COVID-19 Pandemic

Current status of authorisations for combating COVID-19

Applications  received by Swissmedic for the authorisation (or authorisation extension in the case of vaccines) for COVID-19 vaccines and therapeutic agents against COVID-19 and the current status of the authorisation procedures.

Empfehlung des Bundesrates: Bleiben Sie zu Hause, insbesondere, wenn Sie alt oder krank sind

Information on the current situation in Switzerland

Information for health professionnals, FAQs, recommendations for travellers.

Official information page

FAQ on the COVID-19 vaccines

On this page you’ll find answers to frequently asked questions about mRNA vaccines.

All about the vaccines - briefly and concisely explained

Vaccines: Rapid solution for new diseases?

Swismedic - The way a vaccination works

How an mRNA vaccine works

How a vector vaccine works?

How a protein vaccine works

How is the safety of vaccines monitored?

Communication regarding COVID-19


Out-of-Stock – COVID-19 – Authorisations for the temporary import and distribution of human medicines – Update

Licences in accordance with art. 22 para. 3 of the COVID 19 Ordinance 3


Swissmedic approves bivalent Pfizer Ltd. COVID-19 Original / Omicron BA 4-5 booster dose for adults aged 12 and over

Bivalent Original / Omicron BA.4-5 mRNA vaccine (tozinameran / famtozinameran) approved


Comirnaty® COVID-10 vaccines from Pfizer AG: authorisation without special conditions approved

Three formulations (authorisation nos. 68225 and 68710, with 30 and 10 μg/dose) authorised for five years


Swissmedic issues unlimited authorisation* for booster dose of Moderna's bivalent COVID-19 Original / Omicron BA.4-5 vaccine

Spikevax bivalent Original / Omicron BA.4-5 mRNA vaccine authorised for people aged 18 and over


Reports of suspected adverse reactions to COVID-19 vaccines

16,855 reports of suspected adverse vaccination reactions evaluated


Validity of GMP certificates during the COVID-19 pandemic

Update of the validity period of EMA GMP certificates


Reports of suspected adverse reactions to COVID-19 vaccines

16,212 reports of suspected adverse vaccination reactions evaluated


Moderna applies to Swissmedic for authorisation of a second bivalent COVID-19 vaccine

Application submitted for Spikevax Bivalent Original / Omicron BA.4-5 (mRNA-1273.222)